Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Himoto, Takashi ^a   Tani, Joji ^a   Miyoshi, Hisaaki ^a   Morishita, Asahiro ^a   Yoneyama, Hirohito ^a   Kurokohchi, Kazutaka ^a   Inukai, Michio ^a   Masugata, Hisashi ^a   Goda, Fuminori ^a   Senda, Shoichi ^a   Haba, Reiji ^a   Ueno, Masaki ^a   Yamaoka, Genji ^b   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD36; Hepatic steatosis; Hepatitis C virus; Insulin resistance; Oxidized low density lipoprotein

Indexed keywords

CD36 PROTEIN; INSULIN; SCAVENGER RECEPTOR B; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KUPFFER CELL; LIVER; LIVER SINUSOID; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 84883736439     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-51     Document Type: Article

References (40)

1. Clinical practice. Chronic hepatitis C infection. Rosen HR, N Engl J Med 2011 364 2429 2438
2. Hepatitis C, as a metabolic disease: implication for the pathogenesis of NASH. Koike K, Hepatol Res 2005 33 145 150
3. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathologic data. Negro F, Sanyal AJ, Liver Int 2009 S2 26 37
4. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J, World J Gastroenterol 2007 13 4699 4706
5. Hepatitis C virus infection and diabetes: direct involvement of the in the development of insulin resistance. Shintani Y, Fujie H, Miyoshi H, Tsutusumi T, Tsukamoto K, et al. Gastroenterol 2004 126 840 848
6. Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. Hepatol 2003 38 75 85
7. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Romero-Gomez M, Del Mar VM, Andrade RJ, Salmeron J, Diago M, et al. Gastroenterol 2005 128 636 641
8. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, et al. Hepatol 2012 55 1038 1047
9. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L, Gut 2005 54 1003 1008
10. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, et al. World J Gastroenterol 2010 16 2265 2271
11. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. Koike K, Moriya K, J Gastroenterol 2005 40 329 336
12. Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. Himoto T, Yoneyama H, Deguchi A, Kurokohchi K, Inukai M, et al. Exp Ther Med 2010 1 707 711
13. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, et al. Nutr Res 2011 31 829 835
14. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. Febbraio M, Hajjar DP, Silverstein RL, J Clin Invest 2001 108 785 791
15. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. Cai L, Wang Z, Ji A, Meyer JM, van der Westhuyzen DR, PLoS One 2012 7 36785
16. Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading-cDNA and protein array study. Tuomisto TT, Riekkinen MS, Viita H, Levonen AL, Yla-Herttuala S, Atherosclerosis 2005 180 283 291
17. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Griffin E, Re A, Hamel N, Fu C, Bush H, et al. Nat Med 2001 7 840 846
18. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Sampsom MJ, Davies IR, Braschi S, Ivory K, Hughes DA, Atherosclerosis 2003 167 129 134
19. Hepatic fatty acid transporter cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, et al. Gastroenterol 2008 134 556 567
20. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Koonen DPY, Jacobs RL, Febbraio M, Young ME, Soltys CLM, et al. Diabetes 2007 56 2863 2871
21. CD36 deficiency associated with insulin resistance. Miyaoka K, Kuwasako T, Hirano K, Kozai S, Yamashita S, Matsuzawa Y, Lancet 2001 357 686 687
22. The human scavenger receptor class B type 1 is a novel candidate receptor for the hepatitis C virus. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. EMBO J 2002 21 5017 5025
23. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, et al. Gut 2011 60 1394 1402
24. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Handberg A, Levin K, Hojlund K, Beck-Nielsen H, Circulation 2006 114 1169 1176
25. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW, Clin Endocrinol Metab 2010 95 1939 1946
26. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lau JY, Davis GL, Kinffen J, Qian KP, Urdea MS, et al. Lancet 1993 341 1501 1504
27. Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. Sandres-Saune K, Abravanel F, Nicot F, Peron JM, Alric L, et al. J Med Virol 2007 79 1821 1826
28. A proposed system for nomenclature of hepatitis C viral genotypes. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, et al. Hepatology 1994 19 1321 1324
29. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, et al. Int Hepatol Commun 1996 6 112 119
30. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Brunt EM, Janney CG, Bisceglie D, Neuschwander-Tetri BA, Bacon BR, Am J Gastroenterol 1999 94 2467 2474
31. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis in regulated by leptin-mediated signaling. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, et al. Cell Metab 2012 16 44 54
32. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF, J Thromb Haemost 2011 9 844 851
33. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Nakhjavani M, Mashayekh A, Khalilzadeh O, Asgarani F, Morteza A, et al. Clin Res Hepatol Gastroenterol 2011 35 111 116
34. A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signaling. Kennedy DJ, Kuchibhotla S, Westfall KM, Silverstein RL, Morton RE, Febbraio M, Cardiovasc Res 2011 89 604 613
35. Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose torelance. Fernandez-Real JM, Handberg A, Ortega F, Hojlund K, Vendrell J, Richart W, J Nutr Biochem 2009 20 477 484
36. Obesity and Nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Fabbrini E, Sullivan S, Klein S, Hepatol 2010 51 679 689
37. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linke to CD81. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, et al. Hepatol 2007 46 1722 1731
38. Interferon a decreases expression of human scavenger receptor class B1, a possible HCV receptor in hepatocytes. Murao K, Imachi H, Yu X, Cao WM, Nishiuchi T, et al. Gut 2008 57 664 671
39. Phenotype-genotype correlation in CD36 deficiency type I and II. Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, et al. Thromb Haemost 2000 84 436 441
40. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Furuhashi M, Ura N, Nakata T, Shimamoto K, Diabetes Care 2003 26 471 474